Tirzepatide, the drug in Mounjaro, slows gastric emptying, which can make absorption of oral medicines less predictable. That matters most if your HRT is taken by mouth. In practice, the question is not whether the two treatments “cancel each other out”, but whether your HRT route still gives steady symptom control.
What the interaction is, and why it matters
A British Menopause Society Tool for Clinicians published on 16 April 2025, titled *Use of incretin-based therapies in women using hormone replacement therapy (HRT)*, covers incretin-based therapies used for diabetes and obesity that mimic gut hormones regulating insulin, appetite and satiety. Tirzepatide delays gastric emptying, which can affect how quickly oral medicines are absorbed.
That is the practical issue for perimenopause care. If your HRT is a tablet, a slower or less predictable absorption pattern can mean the hormone level in your system is less stable than before. The concern is not a known dangerous drug-drug clash; it is a control problem, where symptoms can reappear if the medication is not being absorbed as expected.
Which HRT is most likely to be affected
Oral HRT is the main concern because it has to pass through the stomach and gut before it is absorbed. If that process slows, you may notice breakthrough hot flushes, poorer sleep, mood changes, or irregular bleeding. Those changes do not automatically mean the combination is unsafe, but they do mean the treatment plan may need review.
Non-oral options are often the cleaner fit when absorption is uncertain. In UK menopause practice, that usually means discussing transdermal options such as patches or gels, because they bypass the gut entirely. UK menopause guidance focuses on reviewing the route of administration rather than simply increasing tablet doses.
Why the issue often appears when starting or titrating Mounjaro
The interaction is most relevant when starting tirzepatide or increasing the dose. That fits the pharmacology: gastric emptying changes can be most noticeable around dose changes, especially before your body has settled into a new routine.
That is why women who are already stable on HRT may still see changes after a Mounjaro dose step-up. The pattern to watch is not just weight loss, but whether menopause symptoms begin to drift back or bleeding becomes different from your baseline. Those are the signals that the absorption question needs a clinician’s attention.
What the wider evidence says
The biological case is not based on menopause guidance alone. A 2024 article in the *Journal of the American Pharmacists Association*, *The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception*, concluded that tirzepatide could have a greater impact on absorption of oral hormonal contraceptives than other GLP-1 receptor agonists. That paper is about contraception rather than HRT, but it supports the same mechanism: oral hormones can be vulnerable when gastric emptying is slowed.
UK-linked patient information issued in 2025 states that GLP-1 agonists such as tirzepatide and semaglutide may reduce absorption of oral medicines because they slow gastric emptying.
What UK professional guidance now asks prescribers to do
The Primary Care Pharmacy Association published a resource in April 2025 on injectable weight loss drugs, contraception and HRT, with a next review date of April 2028. It directs health professionals to consider route of delivery, symptom control and medication review together.
Do not change HRT on your own because you started Mounjaro. If symptoms are controlled, the combination may be fine with monitoring. If symptoms break through, the safer move is a clinician review of the HRT route, the Mounjaro dose stage, and any other oral medicines that could be affected.
What to ask before you combine the two
Before you start tirzepatide, or if you are already taking it and want HRT reviewed, these are the questions that matter:
- Is my HRT oral, or would a non-oral route be better?
- If I’m on tablets, should I expect symptom changes when I start or step up Mounjaro?
- What bleeding changes mean I need review?
- Could any other oral medicines be affected by delayed gastric emptying?
- Who should I contact first if my flushes, sleep or mood worsen?
The University of Sussex Health Centre published its HRT, perimenopause and menopause page on 25 June 2025 with an NHS menopause link. By 24 July 2026, Asda Online Doctor was carrying a dedicated page on Mounjaro and HRT, and Numan had updated its own article on combining HRT with weight-loss medicines on 2 July 2026.
When to see your GP
See your GP, or the clinician who prescribed your HRT, if you get new breakthrough bleeding, a return of hot flushes, night sweats, poor sleep or mood changes after starting Mounjaro or increasing the dose. You should also seek review if you are not sure whether your HRT is oral, or if you are considering switching from tablets to a patch or gel.